Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid intravenous versus intra-articular dosing in primary hip arthroplasty for osteoarthritis
ACTRN12616000907448Phase 4Recruiting
- Sponsor
- David Campbell
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tranexamic acid in osteoarthritis (OA) (2 arms), sponsored by David Campbell. Primary endpoints: Change in hemoglobin, Number of transfusions and 1 more. Started Jun 2016; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12616000907448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000907448.